Cholelithiasis associated with medroxyprogesterone acetate therapy in men

W. J. Meyer, I. Wiener, L. E. Emory, C. M. Cole, N. Isenberg, C. J. Fagan, J. C. Thompson

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Five out of forty-five adult men, 50 years of age or less, who had received, for at least six months, medroxyprogesterone acetate (MPA, Depo Provera(R)) IM, 200-400 mg/week, for prevention of sex-offending or genital- mutilating behavior developed symptomatic cholelithiasis. Thirty of these men were studied with gallbladder ultrasound prospectively off MPA and at six- month intervals while taking the medication and then six months off MPA. Gallstones recovered from two patients were found to have very high cholesterol content, suggesting they were formed in cholesterol supersaturated bile. These findings are consistent with the increased incidence of gallbladder disease related to high-progesterone states and suggest that MPA may be a causative agent in cholelithiasis. The physiologic studies on gallbladder contraction and cholecystokinin release in a subset of the patients failed to provide information on a mechanism for the possible increased incidence of gallbladder disease.

Original languageEnglish (US)
Pages (from-to)69-84
Number of pages16
JournalResearch Communications in Chemical Pathology and Pharmacology
Issue number1
StatePublished - 1992

ASJC Scopus subject areas

  • General Pharmacology, Toxicology and Pharmaceutics
  • Pathology and Forensic Medicine
  • Toxicology
  • Pharmacology


Dive into the research topics of 'Cholelithiasis associated with medroxyprogesterone acetate therapy in men'. Together they form a unique fingerprint.

Cite this